Antitumor effects of a Toxoplasma mutant lacking lactate dehydrogenases
Authors:
- 18 August 2021
- journal article
- research article
- Published by Springer Nature in Parasitology Research
- Vol. 120 (9) , 3335-3339
Abstract
“Bug as drug” is a concept recognized over a century ago and has gained significant research attention recently for fighting diseases such as immune disorders and others. Bacteria and viruses are constantly studied for this purpose, but the use of parasitic organisms is still rare. Recently, we found that Toxoplasma gondii mutants lacking two lactate dehydrogenases (ME49 Δldh1-Δldh2) were avirulent in mice but able to stimulate high levels of Th1 immunity. This outcome prompted us to determine whether Δldh mutants also displayed antitumor activities. Using a mouse melanoma model, we showed that intratumoral administration of Δldh1-Δldh2 repressed the growth of established tumors and helped to inhibit lethal tumor development in the mice. The sera of parasite-treated mice had high levels of TNF-α and INF-γ, which likely contributed to the tumor-repressing activity. We also found that chronic Toxoplasma infection, which is common in animals and humans, also led to antitumor activity. In addition, pre-existing chronic infections did not affect the antitumor efficiency of the Δldh1-Δldh2 mutant. Together, these results suggest that the attenuated T. gondii mutant Δldh1-Δldh2 has the potential to be a good antitumor therapy and provide new insights into the development of novel tumor therapeutics.Keywords
This publication has 20 references indexed in Scilit:
- Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatmentAnti-Cancer Drugs, 2016
- AttenuatedToxoplasma gondiiStimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell PopulationsCancer Immunology Research, 2015
- Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccinesTrends in Parasitology, 2013
- Immune-Mediated Regression of Established B16F10 Melanoma by Intratumoral Injection of Attenuated Toxoplasma gondii Protects against RechallengeThe Journal of Immunology, 2013
- Cancer immunotherapy comes of ageNature, 2011
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Tumor-Resident CD8+ T-cell: The Critical Catalyst in IL-12-Mediated Reversal of Tumor Immune SuppressionArchivum Immunologiae et Therapiae Experimentalis, 2010
- Spontaneous regression: a hidden treasure buried in timeMedical Hypotheses, 2002
- De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondiiNature, 2002
- Resistance to Murine Tumors Conferred by Chronic Infection with Intracellular Protozoa, Toxoplasma gondii and Besnoitia jellisoniThe Journal of Infectious Diseases, 1971